VXA‑G1.1-NN (Norovirus)

VXA-G1.1-NN is an Oral Vaccine Tablet addressing Norovirus.

The clinical trial is a Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Norovirus Vaccine (VXA‑G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers.